KPTI Karyopharm Therapeutics Inc
8,005
$1.09
$0.02
(1.87%)
| Watchers | 8,005 |
| 52-Wk Low | $0.6174 |
| 52-Wk High | $2.67 |
| Market Cap | $126.95M |
| Volume | 1.13M |
| 52-Wk High | $2.67 |
| 52-Wk Low | $0.6174 |
Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare ConferencePR Newswire • 4 days ago
Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference PR Newswire NEWTON...
Share to Feed
Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029 Karyopharm Announces Significant Refinancing...
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress PR...
Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024 Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024 PR Newswire NEWTON, Mass., May 2, 2024 -- Conference...
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON...
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON...
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink...
Karyopharm Therapeutics Inc. (NASDAQ:KPTI Free Report) Equities researchers at Leerink Partnrs issued their Q1 2024 EPS estimates for Karyopharm Therapeutics in a research report...
Karyopharm Therapeutics (NASDAQ:KPTI Free Report) had its price objective lowered by HC Wainwright from $10.00 to $8.00 in a report issued on Friday morning, Benzinga reports. The firm...
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON...